Medigene AG

XETRA MDG1.DE

Medigene AG Current Liabilities for the year ending December 31, 2023: USD 7.92 M

Medigene AG Current Liabilities is USD 7.92 M for the year ending December 31, 2023, a -0.12% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.
  • Medigene AG Current Liabilities for the year ending December 31, 2022 was USD 7.93 M, a -13.24% change year over year.
  • Medigene AG Current Liabilities for the year ending December 31, 2021 was USD 9.14 M, a -26.11% change year over year.
  • Medigene AG Current Liabilities for the year ending December 31, 2020 was USD 12.38 M, a 7.87% change year over year.
  • Medigene AG Current Liabilities for the year ending December 31, 2019 was USD 11.47 M, a 13.64% change year over year.
Key data
Date Current Liabilities Total Non-Current Liabilities Shareholders' Equity Long-Term Debt
Market news
SV Wall Street
XETRA: MDG1.DE

Medigene AG

CEO Dr. Selwyn Ho MB BS, MBBS
IPO Date June 30, 2000
Location Germany
Headquarters Lochhamer Strasse 11
Employees 87
Sector Healthcare
Industries
Biotechnology Pharmaceuticals Vaccines
Description

Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies with a focus on T cell receptor-modified T cells in the areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with 2seventy bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Université de Montréal; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.

Similar companies

EVT.DE

Evotec SE

USD 9.34

7.68%

StockViz Staff

February 6, 2025

Any question? Send us an email